Sec Form 4 Filing - SQUINTO STEPHEN P @ Chemomab Therapeutics Ltd. - 2021-04-19

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person SQUINTO STEPHEN P 2. Issuer Name and Ticker or Trading Symbol Chemomab Therapeutics Ltd. [ CMMB] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 930 5TH AVE, APT 18A 3. Date of Earliest Transaction (MM/DD/YY) 04/19/2021 (Street) NEW YORK, NY10021 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price American Depositary Shares ( 1 ) ( 2 ) 47,938 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Option to Purchase American Depositary Shares $ 27.26 04/19/2021 A 23,768 ( 3 ) 04/19/2031 American Depositary Shares ( 2 ) 23,768 $ 0 23,768 D Option to Purchase American Depositary Shares ( 1 ) $ 0.67 ( 4 ) 11/18/2025 American Depositary Shares ( 2 ) 424 424 D Option to Purchase American Depositary Shares ( 1 ) $ 0.8 ( 4 ) 09/13/2026 American Depositary Shares ( 2 ) 2,109 2,109 D Option to Purchase American Depositary Shares ( 1 ) $ 1.49 ( 5 ) 11/19/2027 American Depositary Shares ( 2 ) 21,095 21,095 D Option to Purchase American Depositary Shares ( 1 ) $ 1.49 ( 4 ) 10/21/2028 American Depositary Shares ( 2 ) 32,928 32,928 D Option to Purchase American Depositary Shares ( 1 ) $ 1.48 ( 6 ) 11/19/2030 American Depositary Shares ( 2 ) 40,362 40,362 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other SQUINTO STEPHEN P 930 5TH AVE, APT 18A NEW YORK, NY10021 X Signatures /s/ Matthew Rudolph, Esq., Attorney-in-Fact for Stephen Squinto 04/21/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. ( 2 )Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. ( 3 )These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service. ( 4 )These options have vested and are exercisable as of the date hereof, subject to the Reporting Person's continued service. ( 5 )14,059 of these options to purchase ADSs have vested and are exercisable as of the date hereof, while the remaining 7,036 of these options will vest and become exercisable in three installments, with 1/3 of the options vesting on each three month anniversary commencing on May 16, 2021, subject to the Reporting Person's continued service. ( 6 )5,042 of these options to purchase ADSs have vested and are exercisable as of the date hereof, while the remaining 35,320 of these options will vest and become exercisable in seven installments, with 1/7 of the options vesting on each three month anniversary commencing on May 19, 2021, subject to the Reporting Person's continued service.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.